CD200抗体;CD200 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CD200 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Raji cells using CD200 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of K562 cells using CD200 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of THP-1 cells using CD200 mouse mAb (green) and negative control (red).    

  
  

The CD200 antibody targets the CD200 glycoprotein, a cell surface molecule belonging to the immunoglobulin superfamily. CD200. also known as OX-2. functions as an immunoregulatory protein by interacting with its receptor, CD200R, primarily expressed on myeloid cells such as macrophages, dendritic cells, and microglia. This interaction delivers inhibitory signals that suppress immune activation, promoting immune tolerance and reducing inflammatory responses. Dysregulation of the CD200-CD200R axis is implicated in autoimmune diseases, cancer immune evasion, and chronic infections, making it a therapeutic target.

In cancer, tumor cells often overexpress CD200 to dampen antitumor immunity by engaging CD200R on immune cells, thereby inhibiting their effector functions. CD200-blocking antibodies aim to disrupt this interaction, restoring immune cell activity against tumors. Preclinical studies show that anti-CD200 antibodies enhance T-cell responses and reduce immunosuppressive myeloid cell activity. Clinical trials, such as those involving samalizumab, have explored their potential in hematologic malignancies like chronic lymphocytic leukemia and multiple myeloma, though outcomes have been mixed, highlighting the need for further optimization.

In autoimmune and inflammatory disorders, CD200 agonists or antagonists are being investigated to modulate immune hyperactivity. For example, enhancing CD200 signaling could suppress excessive inflammation in diseases like rheumatoid arthritis. However, challenges remain, including understanding tissue-specific CD200/CD200R dynamics and minimizing off-target effects. Overall, CD200 antibodies represent a promising but complex therapeutic avenue, requiring deeper mechanistic insights to balance efficacy and safety.